Abstract
Twenty-five evaluable, ambulatory outpatients with disseminated malignant melanoma received tamoxifen at a dose of 40 mg orally each day. None of the patients had an objective regression and approximately 70% had disease progression within 30 days of starting treatment, including two patients with detectable estrogen receptor titers. Median survival time and time to progression were 4 months and 1 month respectively. Performance score was the most significant covariate for survival time (P<0.01) and time to progression (P = 0.02).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 199-201 |
| Number of pages | 3 |
| Journal | Cancer Treatment Reports |
| Volume | 64 |
| Issue number | 2-3 |
| State | Published - Nov 18 1980 |
ASJC Scopus subject areas
- Oncology
- Cancer Research